Pure Bioscience (OTCMKTS:PURE) posted its earnings results on Wednesday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01), Bloomberg Earnings reports. The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.25 million. Pure Bioscience had a negative return on equity of 260.04% and a negative net margin of 460.07%.
Shares of Pure Bioscience stock opened at $0.67 on Friday. Pure Bioscience has a twelve month low of $0.55 and a twelve month high of $1.36. The stock has a market capitalization of $45.60, a price-to-earnings ratio of -6.75 and a beta of -1.35.
In other Pure Bioscience news, CEO Henry R. Lambert sold 41,500 shares of Pure Bioscience stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $0.93, for a total value of $38,595.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.56% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/pure-bioscience-pure-announces-earnings-results.html.
About Pure Bioscience
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds.
Receive News & Ratings for Pure Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pure Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.